FACULTY AFFILIATIONS AND DISCLOSURES

As a provider accredited by the Accreditation Council for Continuing Medical Education, it is the policy of Research To Practice to require the disclosure of any significant financial interest or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:

Kathy D Miller, MD Sheila D Ward Scholar of Medicine, Assistant Professor of Medicine, Department of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana
Grants/Research Support: AstraZeneca Pharmaceuticals LP, Aventis Pharmaceuticals Inc, Medarex Inc, Pfizer Inc, Roche Laboratories Inc
Consultant: Eli Lilly and Company
Honorarium: Genentech BioOncology, Novartis Pharmaceuticals

Mark D Pegram, MD Associate Professor of Medicine, David Geffen School of Medicine at UCLA, Director, Women’s Cancer Program-UCLA/Jonsson Comprehensive Cancer Center, Los Angeles, California Consultant and Honorarium: Roche Laboratories Inc

Gabriel N Hortobagyi, MD Professor of Medicine, Nellie B Connally Chair in Breast Cancer, Chairman, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Consultant: Pfizer Inc
Honorarium: AstraZeneca Pharmaceuticals LP, Aventis Pharmaceuticals Inc, Pfizer Inc

Adam M Brufsky, MD, PhD Assistant Professor of Medicine, University of Pittsburgh, Member, University of Pittsburgh Cancer Institute, Director, Comprehensive Breast Cancer Center, Associate Division Chief, University of Pittsburgh, Department of Medicine, Division of Hematology/Oncology, Pittsburgh, Pennsylvania Grants/Research Support, Consultant and Honorarium: AstraZeneca Pharmaceuticals LP, Aventis Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech BioOncology

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

ERRATUM

In the previous issue of Breast Cancer Update (Volume 3, Issue 8), the Grand Rounds slide 4.22 contained an inverted color key. The dark blue color should represent XT (n=255) and the light blue color should represent docetaxel (n=256). For a replacement slide, please visit the website at www.breastcancerupdate.com/erratum.

Home · Search